5-Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S-1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer (JCOG1202A1)

被引：0

作者：

Mitsunaga, Shuichi ^{[1
,2
]}

Ikeda, Masafumi ^{[1
]}

Nomura, Shogo ^{[3
]}

Morizane, Chigusa ^{[4
]}

Todaka, Akiko ^{[5
]}

Yamamoto, Naoto ^{[6
]}

Kamata, Ken ^{[7
]}

Yanagibashi, Hiroo ^{[8
]}

Mizuno, Nobumasa ^{[9
]}

Kawamoto, Yasuyuki ^{[10
]}

Gotoh, Kunihito ^{[11
]}

Shirakawa, Hirofumi ^{[12
]}

Okano, Naohiro ^{[13
]}

Nomura, Tatsuya ^{[14
]}

Tanaka, Kazunari ^{[15
]}

Takahashi, Amane ^{[16
]}

Yagi, Shintaro ^{[17
]}

Ohta, Koji ^{[18
]}

Takayama, Yukiko ^{[19
]}

Miwa, Haruo ^{[20
]}

Nagano, Hiroaki ^{[21
]}

Kojima, Yasushi ^{[22
]}

Hisano, Terumasa ^{[23
]}

Tahara, Munenori ^{[24
]}

Sakuma, Yasunaru ^{[25
]}

Arai, Hiroyuki ^{[26
]}

Nakamura, Ikuo ^{[27
]}

Katayama, Hiroshi ^{[3
]}

Konishi, Masaru ^{[28
]}

Ueno, Makoto ^{[29
]}

Japan Clinical Oncology Grp JCOG HBPOG

机构：

[1] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan

[2] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Biomarker Discovery, Kashiwa, Japan

[3] Natl Canc Ctr, JCOG Data Ctr, Operat Off, Tokyo, Japan

[4] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan

[5] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Sunto, Japan

[6] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Yokohama, Japan

[7] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan

[8] Chiba Canc Ctr, Dept Hepatobiliary & Pancreat Surg, Chiba, Japan

[9] Aichi Canc Ctr Hosp, Dept Gastroenterol, Nagoya, Japan

[10] Hokkaido Univ Hosp, Div Canc Ctr, Sapporo, Japan

[11] NHO Osaka Natl Hosp, Dept Surg, Osaka, Japan

[12] Tochigi Canc Ctr, Dept Hepatobiliary Pancreat Surg, Utsunomiya, Japan

[13] Kyorin Univ, Fac Med, Dept Med Oncol, Tokyo, Japan

[14] Niigata Canc Ctr Hosp, Dept Digest Surg, Niigata, Japan

[15] Teine Keijinkai Hosp, Ctr Gastroenterol, Sapporo, Japan

[16] Saitama Canc Ctr, Dept Gastroenterol Surg, Saitama, Japan

[17] Kanazawa Univ, Dept Hepatobiliary Pancreat Surg & Transplantat, Kanazawa, Japan

[18] NHO Shikoku Canc Ctr, Dept Thorac Surg, Matsuyama, Japan

[19] Tokyo Womens Med Univ, Inst Gastroenterol, Dept Internal Med, Tokyo, Japan

[20] Yokohama City Univ, Med Ctr, Gastroenterol Ctr, Yokohama, Japan

[21] Yamaguchi Univ, Grad Sch Med, Dept Gastroenterol Breast & Endocrine Surg, Ube, Japan

[22] Natl Ctr Global Hlth & Med, Dept Gastroenterol, Tokyo, Japan

[23] NHO Kyushu Canc Ctr, Dept Hepatobiliary Pancreatol, Fukuoka, Japan

[24] Sapporo Kosei Gen Hosp, Dept Surg, Sapporo, Japan

[25] Jichi Med Univ, Dept Surg, Shimotsuke, Japan

[26] St Marianna Univ, Sch Med, Dept Clin Oncol, Kawasaki, Japan

[27] Hyogo Med Univ, Dept Gastroenterol Surg, Kobe, Hyogo, Japan

[28] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Surg, Kashiwa, Japan

[29] Kanagawa Canc Ctr, Div Hepatobiliary & Pancreat Med Oncol, Yokohama, Japan

来源：

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES | 2024年 / 31卷 / 12期

关键词：

5-FU metabolic pathway; adjuvant; biliary tract cancer; DPD; S-1; DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDYLATE SYNTHASE; EXPRESSION LEVELS; MESSENGER-RNA; THYMIDINE PHOSPHORYLASE; SENSITIVITY; TUMORS; CELLS;

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

BackgroundS-1, an oral fluoropyrimidine derivative, is standard adjuvant therapy for resected biliary tract cancer (BTC), based on the results of the JCOG1202, a phase III trial evaluating the survival benefit with adjuvant S-1 following curative resection for BTC compared to surgery alone. This multicenter ancillary study of the JCOG1202 aimed to evaluate the prognostic impact of the 5-fluorouracil (5-FU) metabolic pathway genes including thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD).MethodsThe 5-FU metabolic pathway genes were measured in tumor cells from formalin-fixed paraffin-embedded resected specimens from 183 patients (surgery alone: n = 94; adjuvant S-1: n = 89). We randomly divided them into training (n = 96) and validation sets (n = 87) for evaluating the interaction between gene levels and RFS benefits in the treatment arm.ResultsRFS benefits of adjuvant S-1 were observed in the low DPD (HR = 0.440 and 0.748, respectively in the training and validation sets) and the low TP groups (HR = 0.709 and 0.602, respectively). Clinicopathological characteristics were well balanced between low and high DPD populations. More advanced stage tumors were observed in high TP populations as compared to those in low TP populations (p = .0332).ConclusionThe results suggest the RFS benefit of adjuvant S-1 in resected BTC patients with low DPD and low TP gene expressions.

引用

页码：886 / 896

页数：11

共 2 条

[1] 5-Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S-1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer
Mitsunaga, Shuichi
Ikeda, Masafumi
Nomura, Shogo
Morizane, Chigusa
Todaka, Akiko
Yamamoto, Naoto
Kamata, Ken
Yanagibashi, Hiroo
Mizuno, Nobumasa
Kawamoto, Yasuyuki
Gotoh, Kunihito
Shirakawa, Hirofumi
Okano, Naohiro
Nomura, Tatsuya
Tanaka, Kazunari
Takahashi, Amane
Yagi, Shintaro
Ohta, Koji
Takayama, Yukiko
Miwa, Haruo
Nagano, Hiroaki
Kojima, Yasushi
Hisano, Terumasa
Tahara, Munenori
Sakuma, Yasunaru
Arai, Hiroyuki
Nakamura, Ikuo
Katayama, Hiroshi
Konishi, Masaru
Ueno, Makoto
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2024,
[2] A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT)
Nakachi, Kohei
Konishi, Masaru
Ikeda, Masafumi
Mizusawa, Junki
Eba, Junko
Okusaka, Takuji
Ishii, Hiroshi
Fukuda, Haruhiko
Furuse, Junji
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (04) : 392 - 395

← 1 →